The potential of gender-specific tumor pharmacology

Pharmacogenomics

Volumn 8, Issue 3, 2007, Pages 271-274

  Mader, Robert M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; THYMIDYLATE SYNTHASE; VINCRISTINE;

3' UNTRANSLATED REGION; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG METABOLISM; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENDER BIAS; GENE DELETION; GENE EXPRESSION PROFILING; GENE INSERTION; GENETIC POLYMORPHISM; HAND FOOT SYNDROME; HUMAN; INDIVIDUALIZATION; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; META ANALYSIS; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; OVARY CANCER; PHARMACOGENOMICS; RECTUM CANCER; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NEOPLASMS; PHARMACOGENETICS; SEX CHARACTERISTICS;

EID: 33947598147     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.3.271     Document Type: Article

References (24)

1. Ruiz Cantero MT, Angeles Pardo M: European Medicines Agency policies for clinical trials leave women unprotected. J Epidemiol. Community Health 60, 911-913 (2006).
2. Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291, 2720-2726 (2004).
3. Watson MA, Gay L, Stebbings WS et al.: Apolipoprotein E gene polymorphism, and colorectal cancer: gender-specific modulation of risk and prognosis. Clin. Sci (Lond.) 104, 537-545(2003).
4. Milano G, Etienne MC, Cassuto-Viguier E et al.: Influence of sex and age on fluorouracil clearance. J. Clin. Oncol. 10, 1171-1175 (1992).
5. Etienne MC, Lagrange JL, Dassonville O et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12, 2248-2Z53 (1994).
6. Hsiao HH, Yang MY, Chang JG et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother. Pharmacol. 53, 445-451 (2004).
7. Inoue S, Hashiguchi M, Chiyoda T et al.: Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics 8, 41-47 (2007).
8. Gill S, Loprinzi CL, Sargent DJ et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 22, 1797-1806 (2004).
9. Meta-Analysis Group In Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 16, 3537-3541 (1998).
10. Stein BN, Petrelli NJ, Douglass HO et al.: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale Phase III trial. Cancer 75, 11-17 (1995).
11. Tepper JE, O'Connell M, Niedzwiecki D et al.: Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control - final report of intergroup 0114. J. Clin. Oncol. 20, 1744-1750 (2002).
12. Singh S, Parulekar W, Murray N et al.: Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin. Oncol. 23, 850-856 (2005).
13. Mader RM, Steger GG, Rizovski B et al.: Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br. J. Clin. Pharmacol. 40, 209-215 (1995).
14. Ulrich CM, Robien K, McLeod HL: Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer 3, 912-920 (2003).
15. Toffoli G, Russo A, Innocenti F et al.: Effect of methylenetetrahydrofolate reductase 677C>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer 103, 294-299 (2003).
16. Cohen V, Panet-Raymond V, Sabbaghian N et al.: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 9,1611-1615 (2003).
17. Vallbohmer D, Brabender J, Yang DY et ai: Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin. Lung Cancer 7, 332-337 (2006).
18. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenta of irinotecan. J. Clin. Owa. 22, 1382-1388 (2004).
19. Buckley DB, Klaassen CD: Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases(UGTs) in mice. Drug Metab. Dispos. 35, 121-127 (2007).
20. Dally H, Edler L, Jager B et al: The CYP3A4*1B Ballele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenomics 13, 607-618 (2003).
21. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568 (2005).
22. Fukuoka M, Yano S, Giaccone G et al: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-2246 (2003).
23. Andre F, Mazouni C, Hortobagyi GN, Pusztai L: DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. Biochim. Biophys. Acta 1766, 197-204 (2006).
24. Wang Y, Jatkoe T, Zhang Y et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22,1564-1571 (2004).